Human Development

Pediatric obesity: screening and intervention

Clinical Overview and When to Suspect Pediatric Obesity

— Overweight: BMI ≥85th to <95th percentile for age/sex

— Obesity (Class 1): BMI ≥95th percentile

— Class 2 (severe): BMI ≥120% of 95th percentile or ≥35 kg/m²

— Class 3: BMI ≥140% of 95th percentile or ≥40 kg/m²

— Short stature + obesity → think endocrine (hypothyroidism, Cushing, GH deficiency)

— Onset before age 5 + extreme hyperphagia → monogenic (MC4R, leptin, POMC)

— Developmental delay + dysmorphism → syndromic (Prader-Willi, Bardet-Biedl, Alström)

— Rapid weight gain after CNS insult/tumor → hypothalamic obesity

— Medication-induced: atypical antipsychotics (risperidone, olanzapine), glucocorticoids, valproate, insulin

Definition (CDC growth charts, ages 2–19):

Under age 2: use WHO weight-for-length charts; ≥97.7th percentile = overweight (BMI percentiles not validated <2 y)

Epidemiology: ~20% of US children 2–19 have obesity; disproportionately affects Hispanic, non-Hispanic Black, and low-income youth — a social determinants–driven disease

AAP 2023 Clinical Practice Guideline reframes obesity as a chronic, complex disease requiring immediate, intensive treatment at diagnosis — abandoned the prior "watchful waiting" approach

When to suspect a contributing/secondary cause (rather than primary/polygenic obesity):

Primary obesity = tall stature, advanced bone age, normal-to-early puberty

Board pearl: A child with obesity who is shorter than expected for mid-parental height is the classic stem cue to work up an endocrine or syndromic cause — primary obesity almost always accelerates linear growth.

Step 3 management: At every well-child visit ≥2 years, calculate and plot BMI percentile; document trajectory, not just absolute value — a child crossing percentiles upward warrants intervention even if still <85th.

Presentation Patterns and Key History

— Diet: sugar-sweetened beverages (SSBs), fruit/vegetable servings, fast food frequency, portion sizes, skipped breakfast, eating while screen-watching

— Activity: ≥60 min moderate-vigorous daily? PE class? Organized sports?

— Screen time: AAP recommends <1 hr/day ages 2–5, consistent limits ages 6+

— Sleep: <9–12 hr (age-dependent) is an independent risk factor; snoring/witnessed apnea suggests OSA

— Mood/behavior: depression, anxiety, bullying, binge-eating, food insecurity

— Polyuria/polydipsia → T2DM

— Headache, vision changes → idiopathic intracranial hypertension

— Hip/knee pain, limp → SCFE or Blount disease

— Snoring, daytime somnolence, enuresis → OSA

— Menstrual irregularity, hirsutism, acne → PCOS

— RUQ pain or asymptomatic transaminitis → MASLD (formerly NAFLD)

Most pediatric obesity is asymptomatic at presentation — identified on routine BMI screening at well-child visits (USPSTF Grade B: screen ages 6+; AAP: screen 2+)

Targeted history (the "5-2-1-0" framework + AAP additions):

Review of systems red flags triggering targeted workup:

Family history: parental obesity (strongest predictor — both parents with obesity → ~80% risk), T2DM, early CV disease, bariatric surgery, dyslipidemia

Social history (essential at Step 3): food insecurity (use Hunger Vital Signs 2-item screen), neighborhood walkability, access to safe play, school lunch participation, caregiver schedules, cultural food practices

Birth/early-life history: birth weight, gestational diabetes exposure, breastfeeding duration, rapid infant weight gain, antibiotic exposure <2 y

Key distinction: Hyperphagia that is extreme, early-onset (<5 y), and food-seeking behavior despite recent meals points to monogenic obesity (MC4R most common, ~3–5%) — refer to genetics; setmelanotide is FDA-approved for POMC/LEPR/PCSK1 deficiency and Bardet-Biedl.

Physical Exam Findings and Comorbidity Screening

— BP using appropriately sized cuff (bladder ≥40% arm circumference); use age/sex/height-based percentiles (AAP 2017 tables); elevated BP = ≥90th percentile, stage 1 HTN = ≥95th

— Heart rate, growth parameters plotted

— Height, weight, BMI plotted on CDC chart; waist circumference optional but useful for central adiposity

— Mid-parental height comparison — a child below target height with obesity raises concern for endocrine cause

— Papilledema → idiopathic intracranial hypertension (pseudotumor cerebri)

— Goiter → hypothyroidism

— Tonsillar hypertrophy, retrognathia → OSA risk

— Moon facies, dorsocervical fat pad, supraclavicular fullness → Cushing

— Acanthosis nigricans (posterior neck, axillae) → insulin resistance marker, not diagnostic of T2DM but flags need to screen

— Striae: thin pink/white = mechanical stretch (normal); wide, purple, >1 cm = Cushing red flag

— Hirsutism, severe acne → PCOS

— Intertriginous candidiasis, hidradenitis suppurativa

— Limp, restricted hip internal rotation → SCFE (urgent ortho referral, non–weight-bearing)

— Bowing of tibia → Blount disease

— Flat feet, knee valgus

Vitals — every visit:

Anthropometrics:

Head/neck:

Skin:

Cardiopulmonary: murmur, prolonged expiratory phase (asthma comorbidity)

Abdomen: hepatomegaly or RUQ tenderness → MASLD

GU/Tanner staging: premature adrenarche common; in boys, buried penis is often normal-variant from suprapubic fat (counsel families)

MSK:

Neuro/development: developmental delay + obesity → syndromic workup

Board pearl: Acanthosis nigricans alone does not diagnose diabetes — it is a clinical marker prompting HbA1c/fasting glucose screening. Don't skip the lab.

Step 3 management: A child with obesity presenting with hip or knee pain must get bilateral hip films (AP + frog-leg) — SCFE is often bilateral and missed when the contralateral side is asymptomatic.

Diagnostic Workup — Screening Labs at Diagnosis

— Acceptable: TC <170, LDL <110, non-HDL <120, TG <90 (0–9 y) or <130 (10–19 y), HDL >45

— Treat dyslipidemia per NHLBI Integrated Guidelines

— HbA1c, fasting plasma glucose, OR 2-hr OGTT

— Prediabetes: A1c 5.7–6.4%, FPG 100–125, 2-hr 140–199

— T2DM: A1c ≥6.5%, FPG ≥126, 2-hr ≥200, or random ≥200 with symptoms

— Confirm with a second test on a different day unless symptomatic with random ≥200

— ALT >2× ULN (>44 boys, >22 girls in NASPGHAN guidance) persisting >3 months → evaluate for MASLD and rule out other causes (viral hepatitis, autoimmune, Wilson, A1AT)

— TSH ± free T4 only if growth deceleration, fatigue, constipation, cold intolerance, goiter (routine screening NOT recommended — most children with obesity have mildly elevated TSH that normalizes with weight loss, not primary hypothyroidism)

— 24-hr urine free cortisol / overnight dexamethasone suppression only if Cushing features

— Vitamin D if bariatric surgery candidate or symptoms

— Iron studies if menorrhagia or pica

AAP 2023 recommends screening labs at diagnosis of obesity (BMI ≥95th percentile) starting at age 10 (or earlier if puberty has begun), and at overweight (≥85th) if additional risk factors (family history T2DM, high-risk ethnicity, signs of insulin resistance, maternal GDM):

Fasting lipid panel:

Glycemic screening — every 2–3 years if normal:

Liver enzymes (ALT) — every 2 years starting age 9–11 if BMI ≥95th, or ≥85th with risk factors:

BP — already covered; if elevated on ≥3 visits → confirm with ambulatory BP monitoring per AAP

Targeted only if clinical suspicion:

Key distinction: Mildly elevated TSH (5–10) with normal free T4 in a child with obesity is usually an effect of adiposity, not a cause — recheck after weight loss; do not reflexively start levothyroxine.

Board pearl: Use non-HDL cholesterol (TC – HDL) as the preferred lipid screen in youth — it does not require fasting and predicts atherosclerosis better than LDL alone in this population.

Diagnostic Workup — Advanced and Comorbidity-Specific Studies

— Persistent ALT >2× ULN >3 months → abdominal ultrasound (operator-dependent, low sensitivity for early steatosis but rules out structural disease)

— MRI-PDFF quantifies hepatic fat; transient elastography (FibroScan) assesses fibrosis non-invasively

— Liver biopsy remains gold standard for staging steatohepatitis/fibrosis when diagnosis uncertain or progression suspected

— Always exclude: hepatitis B/C serologies, ANA/ASMA, ceruloplasmin (Wilson if <40 y with elevated LFTs), A1AT, celiac panel

— Symptom screen (snoring, gasping, witnessed apnea, daytime sleepiness, enuresis, poor school performance) → polysomnography (gold standard)

— AHI >1 = OSA in children; ≥5 moderate, ≥10 severe

— Home sleep tests not validated in children <13 per AASM

— Confirm with second test

— Obtain GAD-65, IA-2, ZnT8, insulin antibodies to exclude type 1 (especially if DKA, lean, rapid onset) and C-peptide to assess endogenous insulin

— Baseline urine albumin/creatinine ratio, dilated eye exam at diagnosis in T2DM (unlike T1DM where retinal screening starts 3–5 y after dx)

MASLD (metabolic dysfunction–associated steatotic liver disease):

Obstructive sleep apnea:

T2DM workup if A1c ≥6.5%:

PCOS in adolescents (Rotterdam modified): requires BOTH oligo/anovulation (≥2 y post-menarche) AND clinical or biochemical hyperandrogenism; polycystic ovaries on US are NOT used in adolescents (normal multifollicular ovaries common)

Idiopathic intracranial hypertension: headache + papilledema → MRI/MRV brain (rule out venous sinus thrombosis, mass) → LP with opening pressure (>28 cm H₂O in obese children)

SCFE: AP + frog-leg lateral pelvic radiographs — bilateral imaging mandatory

Genetic testing: if early-onset (<5 y) + hyperphagia, or syndromic features — MC4R panel, methylation study for Prader-Willi

CCS pearl: When ordering for a child with obesity + T2DM, your CCS-style order set should include A1c, lipid panel, ALT, urine microalbumin, dilated retinal exam, BP, foot exam, mental health screen — all at diagnosis, then per ADA cadence.

Treatment Logic — AAP 2023 Tiered Framework

— Intensive Health Behavior and Lifestyle Treatment (IHBLT) — ≥26 contact hours over 3–12 months, family-based, addressing nutrition, physical activity, behavior change

— Higher dose = better outcome (dose-response); ideally delivered in motivational-interviewing framework

— USPSTF Grade B recommendation for children ≥6 with obesity

— Stage 1 — Prevention Plus: primary care–delivered counseling, monthly visits, 5-2-1-0 messaging

— Stage 2 — Structured Weight Management: planned diet, supervised activity, behavioral goal-setting

— Stage 3 — Comprehensive Multidisciplinary: RD + behavioral health + exercise specialist; weekly contact early

— Stage 4 — Tertiary Care: pharmacotherapy and/or metabolic-bariatric surgery

— Pharmacotherapy: offer to age ≥12 with obesity (BMI ≥95th) as adjunct to IHBLT

— Metabolic-bariatric surgery: evaluate age ≥13 with severe obesity (BMI ≥120% of 95th or ≥35)

— Ages 2–5: weight maintenance is often appropriate (allow growth into weight)

— Ages 6–11 with obesity: gradual loss of ~1 lb/month

— Ages 12–18 with obesity: ~2 lb/week max acceptable

— Class 2/3 obesity: more aggressive loss targets warranted

Core principle: Treat at diagnosis. Do not delay. Obesity is a chronic disease, not a willpower failure. Watchful waiting is no longer guideline-concordant.

Foundational intervention for ALL patients with overweight/obesity:

Stepwise structure (legacy 4-stage model still useful conceptually):

AAP 2023 adds explicit pharmacotherapy and surgery indications:

Goal-setting:

Motivational interviewing: OARS (Open-ended questions, Affirmations, Reflective listening, Summaries) outperforms directive counseling; assess readiness to change before prescribing behavior

Key distinction: BMI reduction is not the only success metric. Improvements in BP, A1c, ALT, lipids, sleep, quality of life, and weight trajectory all count — emphasize this to families to prevent demoralization.

Step 3 management: Document shared decision-making for any pharmacotherapy or surgery referral, including discussion of alternatives, risks, expected magnitude of effect, and family values.

Pharmacotherapy — FDA-Approved Options in Adolescents

— Semaglutide (Wegovy): FDA-approved ≥12 y; once-weekly SC; ~16% mean BMI reduction at 68 wk (STEP TEEN trial)

— Liraglutide (Saxenda): ≥12 y; daily SC; ~5% BMI reduction

— Mechanism: central appetite suppression, delayed gastric emptying, glucose-dependent insulin secretion

— Side effects: nausea, vomiting, diarrhea (titrate slowly); rare pancreatitis, gallbladder disease

— Contraindications: personal/family history medullary thyroid carcinoma or MEN2 (black box); prior pancreatitis caution

— Counsel about rebound weight gain on discontinuation — this is chronic disease therapy

— Topiramate teratogenicity — cleft lip/palate; pregnancy test before start, contraception counseling, monthly pregnancy testing in those who could become pregnant

— Side effects: paresthesia, cognitive slowing, increased HR, dry mouth, metabolic acidosis

Indication: age ≥12 with BMI ≥95th percentile, as adjunct to IHBLT (AAP 2023). Always continue lifestyle treatment.

GLP-1 receptor agonists (most effective class):

Phentermine/topiramate ER (Qsymia): FDA-approved ≥12 y (2022); ~7% BMI reduction

Orlistat: ≥12 y; lipase inhibitor; modest efficacy (~3% BMI); GI side effects (steatorrhea, fecal urgency) limit adherence; fat-soluble vitamin supplementation needed

Phentermine alone: approved ≥16 y, short-term (≤12 weeks); sympathomimetic — caution with CV disease, hyperthyroidism

Setmelanotide: for genetically confirmed POMC, LEPR, PCSK1 deficiency, and Bardet-Biedl — ≥6 y; daily SC injection

Metformin: NOT FDA-approved for obesity but useful when T2DM or prediabetes coexists; modest weight effect (~1–2 kg); first-line for pediatric T2DM along with lifestyle

Topiramate, bupropion/naltrexone, tirzepatide: not yet pediatric-approved (as of current guidance) — off-label use requires specialist involvement

Board pearl: Semaglutide is the most effective pharmacotherapy in adolescents to date — when a Step 3 stem asks for the most effective adjunct to lifestyle in a 14-year-old with BMI 38, the answer is GLP-1 agonist.

Step 3 management: Before starting GLP-1 in an adolescent, screen for eating disorder history (especially binge eating, bulimia) and suicidal ideation, and review MTC/MEN2 family history.

Metabolic and Bariatric Surgery in Adolescents

— Class 2 obesity (BMI ≥35 or ≥120% of 95th) with a major comorbidity (T2DM, moderate-severe OSA [AHI ≥15], MASLD with fibrosis, idiopathic intracranial hypertension, GERD, severe HTN)

— Class 3 obesity (BMI ≥40 or ≥140% of 95th) with or without comorbidities

— Age ≥13 years (some centers younger if severe); Tanner stage IV–V and ≥95% of adult height preferred but not absolute

— Sleeve gastrectomy (most common): ~80% of stomach removed; restrictive + reduced ghrelin; lower micronutrient risk than bypass

— Roux-en-Y gastric bypass: restrictive + malabsorptive; better T2DM remission, GERD improvement; higher nutritional risk

— Adjustable gastric banding: NOT recommended in adolescents (poor durability, high reoperation)

— Untreated/unstable substance use, untreated psychiatric illness, pregnancy or planned within 12–18 months

— Inability to adhere to lifelong nutritional follow-up

— Medically correctable cause of obesity not yet addressed

— Multivitamin, calcium citrate 1200–1500 mg, vitamin D ≥3000 IU, B12, iron (especially menstruating females), thiamine in first months

— Annual labs: CBC, iron studies, B12, folate, vitamin D, PTH, A, E, K, zinc, copper

Indications (AAP 2023 + ASMBS Pediatric Guidelines 2018):

Procedures:

Outcomes (Teen-LABS): ~25–30% sustained weight loss at 3 years, T2DM remission ~95%, HTN remission ~75%, OSA improvement substantial

Contraindications:

Preoperative workup: multidisciplinary team (surgeon, pediatrician, dietitian, behavioral health, exercise specialist), psychosocial evaluation, comprehensive metabolic and nutritional labs, sleep study, upper GI evaluation if symptomatic

Postoperative nutrition (lifelong):

Complications: anastomotic leak, marginal ulcer, internal hernia (bypass), GERD (sleeve — may worsen), dumping syndrome, nutritional deficiencies, bone density loss, pregnancy malabsorption risk (delay pregnancy 12–18 months; folate critical)

Board pearl: Adolescent bariatric surgery outperforms adult outcomes for T2DM and HTN remission — earlier intervention before comorbid damage accrues is the rationale for moving away from age-based gatekeeping.

Step 3 management: Ensure contraception counseling before surgery in any post-menarcheal female — fertility often improves rapidly, and pregnancy within 12–18 months risks nutritional deficits and poor fetal outcomes.

Special Populations — Comorbid Endocrine and Renal/Hepatic Issues

— Metformin + lifestyle is first-line; titrate to 2000 mg/day

— Add liraglutide or exenatide ER if A1c not at goal (<7%) or if BMI reduction is a priority

— Insulin if A1c >8.5%, ketosis, or symptomatic hyperglycemia at presentation; can often wean as metformin/GLP-1 take effect

— Empagliflozin approved age ≥10 for pediatric T2DM (2023)

— Avoid sulfonylureas in pediatric T2DM (poor durability, hypoglycemia)

— Weight loss is first-line therapy — 7–10% body weight loss can resolve steatohepatitis

— Vitamin E (800 IU/day) considered in biopsy-proven NASH without diabetes (off-label, NASPGHAN)

— Hepatology referral for advanced fibrosis; transplant evaluation if cirrhosis

— Obesity-related glomerulopathy with FSGS pattern possible

— ACE inhibitor for proteinuria; monitor potassium and creatinine

— Pediatric nephrology referral

— LDL ≥190 (or ≥160 with risk factors, or ≥130 with T2DM/severe obesity) despite 6 months lifestyle → statin therapy ≥age 10

— Atorvastatin, rosuvastatin, pravastatin commonly used; baseline ALT, CK

— Hypertriglyceridemia >500 → fibrate or omega-3 to prevent pancreatitis

— Confirmed stage 1 HTN despite 6 months lifestyle → ACEi/ARB or CCB first-line in non-Black patients; thiazide alternative

— Stage 2 HTN or symptomatic → start pharmacotherapy immediately + workup for secondary causes

— Echocardiogram to assess LVH; LVH = end-organ damage and intensifies treatment

— Combined OCPs for menstrual regulation and hyperandrogenism (first-line)

— Metformin for metabolic features

— Weight loss improves ovulation and androgen excess

Coexisting type 2 diabetes:

MASLD with fibrosis:

Chronic kidney disease/proteinuria:

Dyslipidemia (per NHLBI):

Hypertension:

Polycystic ovary syndrome:

Idiopathic intracranial hypertension: weight loss, acetazolamide, ophthalmology co-management; topiramate as adjunct (dual benefit with phentermine/topiramate)

Key distinction: A child with obesity + new proteinuria likely has obesity-related glomerulopathy (FSGS); biopsy may be needed but weight loss + ACEi often markedly improves proteinuria before biopsy is required.

Step 3 management: When initiating a statin in a 12-year-old, baseline ALT/CK, repeat at 4–8 weeks, counsel on muscle symptoms, and document pregnancy counseling in adolescent females (statins category X).

Special Populations — Early Childhood, Pregnancy, and Disability

— Use WHO weight-for-length percentiles, not BMI

— Focus on feeding practices — responsive feeding, avoid SSBs and juice (AAP: no juice <1 y; ≤4 oz/day ages 1–3)

— Breastfeeding ≥6 months reduces childhood obesity risk

— Avoid restrictive dieting; goal is healthy trajectory, not weight loss

— Weight maintenance typically appropriate; allow linear growth into weight

— Family-based behavioral interventions are most effective

— No pharmacotherapy or surgery in this age group except setmelanotide for genetic cases ≥6 y

— Increased risk: GDM, preeclampsia, cesarean delivery, macrosomia, neural tube defects, stillbirth

— Folic acid 4 mg/day (high-dose) in those with prior bariatric surgery or BMI ≥30 (some guidelines suggest 1 mg; high-dose for malabsorptive surgery)

— Discontinue GLP-1 agonists, topiramate, statins before conception

— Post-bariatric: monitor B12, iron, folate, vitamin D; avoid 50-g OGTT after bypass (dumping) — use fasting glucose + A1c or home glucose monitoring for GDM screening

— Higher obesity prevalence; food selectivity, sensory issues, medication effects (atypical antipsychotics)

— Tailor interventions to sensory and communication needs; involve OT, behavioral therapy

— Consider switching from olanzapine/risperidone to lower-weight-gain agents (aripiprazole) when clinically appropriate

— Prader-Willi: hyperphagia, hypotonia, hypogonadism — strict environmental food control essential, growth hormone therapy approved

— Bardet-Biedl: polydactyly, retinal dystrophy, renal anomalies — setmelanotide approved

— Genetic counseling for families

Children <2 years:

Children 2–5 years:

Adolescent pregnancy with obesity:

Children with developmental disabilities / autism spectrum:

Syndromic obesity:

Transgender and gender-diverse youth: weight gain may accompany gender-affirming hormone therapy; integrate obesity care without stigmatizing body changes; collaborate with adolescent medicine

Board pearl: In a child <2 years with rapid weight gain, do not restrict calories — the intervention is anticipatory guidance on feeding practices, eliminating juice/SSBs, and responsive feeding cues.

Step 3 management: A 17-year-old post–sleeve gastrectomy who becomes pregnant 8 months postop needs immediate OB/maternal-fetal medicine referral, high-dose folate, comprehensive micronutrient panel, and counseling about increased risk of small-for-gestational-age infant.

Complications and Adverse Outcomes

— T2DM — pediatric T2DM is more aggressive than adult-onset, with faster beta-cell decline (TODAY study) and earlier microvascular complications

— Hypertension, dyslipidemia, metabolic syndrome

— Early atherosclerosis — autopsy data show fatty streaks in obese adolescents

— Left ventricular hypertrophy in 30–40% of hypertensive obese youth

— MASLD/MASH — leading cause of pediatric liver disease in US; can progress to cirrhosis by young adulthood

— Cholelithiasis (especially during rapid weight loss)

— Obstructive sleep apnea — cognitive impairment, cor pulmonale if untreated

— Obesity hypoventilation syndrome in severe obesity

— Asthma — bidirectional relationship; obesity worsens control, response to inhaled steroids reduced

— Slipped capital femoral epiphysis — peak adolescence; can be bilateral; urgent ortho referral, non–weight-bearing until surgical fixation

— Blount disease (tibia vara) — progressive bowing

— Flat feet, joint pain, decreased physical function

— Idiopathic intracranial hypertension — vision loss if untreated

— Migraine

— PCOS in females; hypogonadism in males (lower testosterone, gynecomastia)

— Early puberty in girls, delayed puberty in boys

— Infertility

— Depression, anxiety, low self-esteem — bidirectional with obesity

— Bullying, weight-based stigma — affects academic performance, social functioning

— Eating disorders — binge eating disorder; bulimia; atypical anorexia nervosa (restrictive behaviors at higher weights but full anorexia psychopathology)

— Suicidality risk elevated

Cardiometabolic:

Hepatic:

Pulmonary:

Musculoskeletal:

Neurologic:

Endocrine/reproductive:

Renal: obesity-related glomerulopathy, FSGS, CKD

Psychosocial (often underweighted on boards but critical):

Oncologic (adult-emerging): obesity in adolescence increases adult risk of endometrial, colorectal, breast, esophageal, renal, pancreatic, and liver cancers

Key distinction: Atypical anorexia nervosa — a previously high-BMI adolescent with rapid weight loss, food restriction, body image distortion, and bradycardia/orthostasis — has the same medical risks as classic anorexia and needs the same level of care, despite "normal" BMI. Don't celebrate weight loss without screening behavior.

Board pearl: A teen with obesity, headache, and transient visual obscurations needs fundoscopy for papilledema → MRI/MRV → LP. Missing IIH risks permanent blindness.

When to Escalate — Referrals, Subspecialty, and Inpatient Care

— BMI ≥120% of 95th percentile (class 2+)

— Failure to improve trajectory after 6 months of primary care–based IHBLT

— Comorbidities requiring coordinated specialty care

— Pharmacotherapy or surgery candidacy

— Suspected secondary obesity (Cushing, hypothyroidism with confirmatory labs, GH issues)

— T2DM with A1c >9% or insulin requirement

— Suspected monogenic/syndromic obesity for genetic workup

— Early-onset (<5 y) extreme obesity with hyperphagia

— Syndromic features (developmental delay, dysmorphism, hypotonia)

— Positive depression screen (PHQ-9 ≥10), suicidality

— Eating disorder concerns — refer to adolescent medicine or eating disorders program

— Bariatric surgery psychosocial evaluation

— DKA or HHS in T2DM

— Severe hypertension with end-organ effects (encephalopathy, retinopathy, AKI)

— Eating disorder with bradycardia (<50 awake, <45 asleep), hypotension, hypokalemia, dehydration — even at "normal" BMI

— Acute SCFE pending surgery

— Severe OSA with cor pulmonale

— Suicidality

— Acute focal neuro deficits, severe headache with papilledema

— Severe abdominal pain (cholecystitis, pancreatitis)

— DKA-like presentation

Multidisciplinary obesity clinic referral:

Endocrinology:

Genetics:

Hepatology: persistent ALT >2× ULN, suspected advanced MASLD, abnormal imaging

Cardiology: stage 2 HTN, LVH on echo, suspected secondary HTN

Sleep medicine: symptoms suggesting OSA → polysomnography; severe OSA → consider adenotonsillectomy, CPAP

Orthopedics — urgent same-day: SCFE (limp, hip/knee pain, restricted internal rotation) → ED or direct ortho referral, non–weight-bearing

Ophthalmology: suspected IIH, T2DM diagnosis (retinal screening at diagnosis)

Behavioral health/psychiatry:

Inpatient admission criteria:

Emergency department:

CCS pearl: A 15-year-old with newly diagnosed T2DM, A1c 12%, ketones positive, but no acidosis → admit for insulin initiation, education, A1c, lipid, microalbumin, dilated eye exam, and behavioral health evaluation; transition to metformin ± GLP-1 as glucotoxicity resolves.

Step 3 management: Always include a mental health screen (PHQ-9 or equivalent) in any escalation decision — depression and obesity reinforce each other and untreated depression undermines every other intervention.

Key Differentials — Other Causes of Excess Weight Gain

— Hypothyroidism: weight gain modest, fatigue, constipation, cold intolerance, growth deceleration — TSH ± free T4; treat with levothyroxine

— Cushing syndrome: central obesity with thin extremities, moon facies, purple striae, hypertension, growth failure — overnight dex suppression, 24-hr urine cortisol, late-night salivary cortisol

— Growth hormone deficiency: central adiposity, short stature, slow growth velocity — IGF-1, GH stimulation testing

— Pseudohypoparathyroidism (Albright hereditary osteodystrophy): short stature, round face, brachydactyly, hypocalcemia, elevated PTH

— After craniopharyngioma resection, cranial irradiation, TBI

— Insatiable hunger, rapid weight gain, often with panhypopituitarism

— Difficult to treat; setmelanotide and GLP-1 agonists studied

— MC4R mutations — most common (~3–5% of severe pediatric obesity); tall stature, hyperinsulinemia

— Leptin deficiency — recombinant leptin (metreleptin) for confirmed cases

— POMC, LEPR, PCSK1 — setmelanotide approved

— SH2B1 — developmental delay + obesity

— Prader-Willi: neonatal hypotonia, poor feeding initially → hyperphagia after age 2, short stature, hypogonadism, intellectual disability, characteristic facies

— Bardet-Biedl: polydactyly, retinal dystrophy, renal anomalies, hypogonadism, intellectual disability

— Alström, Cohen, Smith-Magenis, fragile X — each with distinctive features

— Atypical antipsychotics (olanzapine > risperidone > quetiapine > aripiprazole)

— Glucocorticoids

— Antiepileptics: valproate, gabapentin

— Antidepressants: paroxetine, mirtazapine

— Insulin, sulfonylureas

— Some antihistamines

Within the broader "excess adiposity" category, distinguishing primary (polygenic/lifestyle) obesity from specific etiologies changes management:

Endocrine causes (consider if short stature, growth deceleration, or specific features):

Hypothalamic obesity:

Monogenic obesity (~5% of severe early-onset cases):

Syndromic obesity:

Medication-induced:

Board pearl: MC4R mutation is the most common monogenic obesity — tall, hyperphagic child with severe early-onset obesity and a parent with same phenotype.

Key distinction: Endocrine obesity → short; primary/genetic-polygenic obesity → tall for age. Use linear growth as your first screening filter.

Key Differentials — Mimics and "Looks Like Obesity but Isn't"

— Nephrotic syndrome (proteinuria, hypoalbuminemia, periorbital/dependent edema)

— Heart failure

— Liver failure with ascites

— Severe protein-energy malnutrition (kwashiorkor)

— Distinguishing feature: pitting edema, fluid shifts, rapid weight change rather than gradual

— Generalized congenital lipodystrophy (Berardinelli-Seip): near-total absence of adipose tissue paradoxically with severe insulin resistance, hypertriglyceridemia, hepatic steatosis, acanthosis nigricans

— Familial partial lipodystrophy (Dunnigan): limb fat loss + truncal/facial fat accumulation

— HIV-associated lipodystrophy (rare in current ART era)

— Treatment: metreleptin for select cases

— Athletic adolescents with high BMI but low body fat (e.g., football linemen, weightlifters) — BMI overestimates adiposity

— Use waist circumference, skin folds, or body composition (DXA, bioimpedance) when clinical suspicion of false-positive BMI

Conditions that may simulate or coexist with obesity, requiring distinction:

Generalized edema (anasarca):

Lipodystrophies:

Cushing syndrome (deserves repeat emphasis): central truncal adiposity with thin limbs is the classic mimic — wide purple striae, supraclavicular fat pad, buffalo hump, growth failure, hypertension, hypokalemia distinguish from primary obesity

Muscular hypertrophy / high BMI from lean mass:

Ascites or hepatosplenomegaly: abdominal distention misread as adiposity; palpate and percuss; ultrasound clarifies

Macrocephaly or massive lymphadenopathy: rare contributors to weight without adiposity

Pseudotumor cerebri without obesity: consider tetracyclines, vitamin A toxicity, withdrawal from chronic steroids

Premature adrenarche: body odor, pubic hair before age 8 (girls) or 9 (boys) with advanced bone age — common in obesity; distinguish from true central precocious puberty (breast development, testicular enlargement)

Constitutional growth — "early grower": large for age across height and weight, with normal BMI percentile — not obesity; reassure

Key distinction: A muscular adolescent with BMI 30 but normal blood pressure, normal labs, low waist circumference, and high physical fitness is not obese in any clinically meaningful sense. BMI is a screening tool, not a diagnosis — confirm with adiposity assessment when discordant.

Board pearl: Generalized lipodystrophy can present with severe insulin resistance and acanthosis nigricans without obesity — when a thin child has T2DM-like labs and hepatic steatosis, think lipodystrophy.

Long-Term Plan, Maintenance, and Secondary Prevention

— Nutrition: Mediterranean-style or DASH patterns; reduce ultraprocessed foods, SSBs (target zero); family meals; portion awareness; cooking skills

— Physical activity: ≥60 min daily moderate-vigorous activity (HHS Physical Activity Guidelines); incorporate muscle-strengthening 3×/week; reduce sedentary time

— Sleep hygiene: age-appropriate sleep (9–12 hr school-age, 8–10 hr teens); consistent schedule; no screens in bedroom

— Screen time limits: AAP family media plan; protect mealtimes and sleep

— Mental health: ongoing depression/anxiety screening; treat eating disorders aggressively

— GLP-1 and other anti-obesity medications are maintenance therapies — discontinuation typically results in regain

— Counsel families that this parallels other chronic disease meds (insulin, antihypertensives)

— Monitor for cumulative side effects, micronutrient status, growth, mental health

— Lifelong micronutrient supplementation and annual labs

— Behavioral health follow-up — risk of substance use disorders post-surgery (alcohol especially after RYGB)

— Bone health: DXA every 2 years, calcium/vitamin D optimization

— Plastic surgery referral for excess skin if affecting hygiene/function

— Annual BP, lipid, ALT, A1c surveillance (more frequent if abnormal or on therapy)

— Microalbumin and retinal screening in T2DM

— Repeat polysomnography after significant weight loss if OSA was present

— Plan transition early; identify adult primary care, endocrinology, bariatric program

— Use structured tools (e.g., GotTransition.org)

— Particular vulnerability period — many lose insurance, miss follow-up, regain weight

Obesity is a chronic, relapsing disease requiring lifelong management — frame this with families to set expectations and reduce shame around weight regain.

Maintenance pillars:

Pharmacotherapy continuation:

Post-bariatric surgery:

Secondary prevention of comorbidities:

Family-based approach: parents/caregivers model behaviors; treat the food environment, not just the child; involve siblings; address parental obesity when present

Transition to adult care (ages 18–25):

Board pearl: Stopping GLP-1 agonists typically leads to two-thirds of lost weight regained within a year — this is not failure; it confirms obesity as a chronic disease requiring ongoing therapy.

Step 3 management: Use a written treatment plan at every visit summarizing diet, activity, sleep, screen, and any medication goals, with follow-up cadence — improves adherence and is medicolegally protective.

Follow-Up Cadence, Monitoring, and Counseling

— IHBLT initiation: weekly or biweekly contact, totaling ≥26 hours over 3–12 months (USPSTF/AAP)

— Maintenance phase: every 1–3 months

— Pharmacotherapy: monthly for first 3 months, then every 3 months when stable

— Post-bariatric surgery: 2 weeks, 1, 3, 6, 12 months, then annually

— Anthropometrics: height, weight, BMI percentile, waist circumference (optional)

— Vitals: BP with correct cuff

— Targeted symptoms: hyperphagia, mood, sleep, GI side effects, menses

— Adherence: medication, lifestyle, family engagement

— Labs per comorbidity schedules

— Lipid panel: every 1–2 years if normal; annually if abnormal or on therapy

— A1c/fasting glucose: every 2–3 years if normal; every 3–6 months if T2DM

— ALT: every 1–2 years; more often if elevated

— On GLP-1: lipase only if symptomatic; renal function periodically

— On topiramate: bicarbonate (acidosis); pregnancy testing monthly in those at risk

— On statin: ALT at baseline and after dose changes; CK if symptoms

— Post-bariatric: CBC, iron, B12, folate, vitamin D, PTH, A/E/K, zinc, copper annually

— Affirm efforts and incremental progress

— Use non-stigmatizing language — "child with obesity," not "obese child"

— Avoid focusing exclusively on the scale; celebrate fitness, labs, mood, sleep, function

— Address weight-based bullying explicitly; equip families to advocate

— Avoid restrictive dieting language in children — increases eating disorder risk; emphasize healthy patterns instead

— Screen at every visit for disordered eating, depression, suicidality

— Specific, measurable, achievable goals (e.g., "walk 20 min after dinner 4 days/week")

— Family-based activity preferred

— Physical therapy if joint pain or functional limitations limit activity initiation

— Insurance coverage of anti-obesity meds remains inconsistent (advocate, use prior authorizations)

— Group-based IHBLT and telehealth expand access

— Address food insecurity with WIC, SNAP, school meals, food pantry referrals — clinical interventions fail in food-insecure households without resource support

Visit frequency (intensity = outcomes):

At each visit, monitor:

Lab monitoring cadence:

Counseling priorities (motivational interviewing voice):

Rehab/activity prescriptions:

Health systems considerations:

Board pearl: The single most evidence-based intervention for pediatric obesity is family-based behavioral treatment ≥26 hours — when a stem asks "best initial management," this is the answer over any drug.

Step 3 management: Document food insecurity screening (Hunger Vital Signs) annually; positive screen → connect to community resources before prescribing dietary changes.

Ethical, Legal, and Patient Safety Considerations

— Implicit and explicit weight bias documented in pediatric clinicians — reduces care quality, increases avoidance of care

— Use person-first, non-stigmatizing language ("adolescent with obesity")

— Address weight before discussing it: ask permission ("Would it be okay to talk about weight today?")

— Avoid blame-framed counseling; obesity is a disease with biological, environmental, and genetic drivers

— Adolescents ≥12 should provide assent to pharmacotherapy and surgery

— For bariatric surgery, both parental consent and patient assent required; thorough discussion of irreversibility, lifelong follow-up, nutritional consequences

— Document discussion of alternatives, risks, benefits, expected outcomes

— Severe obesity alone is not child abuse/neglect

— Reportable concerns: medical neglect when caregiver refuses life-saving treatment for life-threatening complications (e.g., severe OSA with cor pulmonale, uncontrolled T2DM with DKA)

— Engage social work, ethics consultation before reporting; emphasize support over punishment

— Food insecurity is not neglect — it is a social determinant requiring resources

— Aggressive weight loss messaging can precipitate eating disorders, especially in vulnerable youth

— Screen for ED symptoms before and during treatment (SCOFF, EDE-Q)

— Atypical anorexia is a real risk in adolescents who lose weight rapidly — monitor for restriction, purging, excessive exercise, body image distortion regardless of current BMI

— Conduct part of every visit with the adolescent alone (typically ≥12 y)

— Discuss confidentiality limits (safety threats to self/others, abuse, mandatory reporting)

— Sensitive topics: substance use, sexual activity, mood, body image

— Pediatric obesity disproportionately affects historically marginalized populations

— Treatment access disparities — bariatric surgery and anti-obesity drugs less available to publicly insured patients

— Clinicians have a role in systemic advocacy, not just individual treatment

— At age 18–21, transition to adult care is a vulnerable window — medication lapses, lost insurance, missed follow-up

— Use formal transition planning, warm handoffs, written summaries

— Post-bariatric young adults are especially at risk for nutritional deficiencies and weight regain during transition

Weight stigma and bias:

Informed consent and assent:

Mandatory reporting and child protection:

Eating disorder safety:

Confidentiality in adolescents:

Health equity:

Transition-of-care risk (Step 3 staple):

Step 3 management: When a parent refuses recommended bariatric surgery for a 15-year-old with class 3 obesity, severe OSA with right heart strain, and T2DM, your response is continued multidisciplinary care, education, ethics consultation, and shared decision-making — not reporting; refusal of an elective procedure with reasonable alternatives is not neglect.

Board pearl: Use "adolescent with obesity," never "obese adolescent" — exam stems and quality measures increasingly enforce non-stigmatizing language.

High-Yield Associations and Rapid-Fire Clinical Facts

BMI cutoffs (age 2–19): ≥85th overweight, ≥95th obesity, ≥120% of 95th severe (class 2), ≥140% of 95th class 3

Under age 2: WHO weight-for-length, not BMI

USPSTF Grade B: screen ≥6 y, offer IHBLT ≥26 contact hours

AAP 2023: treat at diagnosis — no watchful waiting; pharmacotherapy ≥12 y, surgery ≥13 y

Most effective pharmacotherapy in teens: semaglutide (~16% BMI reduction)

GLP-1 black box: medullary thyroid carcinoma, MEN2

Topiramate teratogenicity: cleft lip/palate — pregnancy testing required

Bariatric procedure of choice in adolescents: sleeve gastrectomy (most common); RYGB has best T2DM remission

Banding is NOT recommended in adolescents

Acanthosis nigricans = insulin resistance marker, not diagnostic of T2DM

Mildly elevated TSH in obesity often resolves with weight loss — not primary hypothyroidism

Cushing screen: overnight dex, 24-hr urine cortisol, late-night salivary cortisol

MC4R mutation = most common monogenic obesity

Setmelanotide FDA-approved: POMC, LEPR, PCSK1, Bardet-Biedl, age ≥6

Hypothyroidism, Cushing, GH deficiency → short stature with obesity (primary obesity → tall)

Prader-Willi: neonatal hypotonia → hyperphagia after age 2; uses growth hormone therapy

SCFE: obese adolescent, limp, hip/knee pain, restricted internal rotation → urgent ortho, non–weight-bearing

Blount disease: progressive tibia vara

IIH: headache + papilledema → MRV → LP opening pressure

MASLD ALT cutoffs (NASPGHAN): >44 boys, >22 girls

Pediatric T2DM: confirm with second test, screen microalbumin and retina at diagnosis

NHLBI statin threshold: LDL ≥190 (or ≥160 with risk factors) age ≥10 after 6 months lifestyle

OSA AHI in children: >1 abnormal, ≥5 moderate, ≥10 severe

Adolescent PCOS: requires anovulation + hyperandrogenism; polycystic ovary morphology on US not used

Atypical anorexia: restriction at higher BMI — same medical risks as classic AN

Post-RYGB: avoid 50-g OGTT (dumping); use A1c or home glucose for GDM screening

Mid-parental height formula: boys = [(father + mother)/2] + 6.5 cm; girls = [(father + mother)/2] – 6.5 cm

No juice before age 1; ≤4 oz/day ages 1–3

Breastfeeding ≥6 months reduces obesity risk

Family-based behavioral therapy outperforms individual for kids <12

Board pearl: "Tall child, severe early-onset obesity, hyperphagia, parental obesity" → think MC4R; "short child with obesity" → endocrine workup.

Board Question Stem Patterns

— 10-year-old, BMI 28 (97th %ile), normal labs, sedentary, drinks 24 oz juice daily.

— Best initial step: family-based intensive health behavior and lifestyle treatment; eliminate sugar-sweetened beverages

— Distractors: order TSH (not indicated without growth concerns), prescribe orlistat (wrong age and not first-line), refer to bariatrics (not appropriate at class 1)

— 14-year-old, BMI 36, completed 6 months IHBLT with minimal change, no contraindications.

— Best next step: add semaglutide (GLP-1 RA) to ongoing lifestyle therapy

— Watch for distractors: metformin (only if T2DM/prediabetes), orlistat (less effective), surgery (not yet indicated unless severe comorbidity)

— 16-year-old, BMI 44, severe OSA on CPAP, T2DM on metformin with A1c 8.2, MASLD with ALT 90.

— Best next step: refer to multidisciplinary metabolic-bariatric surgery program

— Distractors: continue medical therapy alone, add insulin, defer until age 18

— 7-year-old with weight gain, fatigue, declining growth velocity, constipation.

— Best next step: TSH and free T4 (short stature + obesity → endocrine workup)

— Distractors: dietary counseling alone, refer to bariatrics

— 13-year-old with obesity, limp, knee pain referred from hip, restricted internal rotation.

— Best next step: bilateral AP and frog-leg pelvic radiographs, non–weight-bearing, urgent ortho referral

— 12-year-old, BMI 33, asymptomatic, ALT 72 on screening.

— Best next step: repeat ALT in 3 months, ultrasound abdomen, exclude viral hepatitis/Wilson/autoimmune; counsel weight loss as first-line

— 15-year-old, BMI 38, A1c 7.8%, no acidosis, acanthosis nigricans.

— Best initial: metformin + lifestyle; obtain microalbumin, dilated eye exam, lipid panel at diagnosis

— 4-year-old, BMI Z-score +5, insatiable hunger from infancy, father had bariatric surgery.

— Best next step: refer to genetics, MC4R panel

— Parent insists clinician "lecture" 11-year-old about laziness causing weight.

— Best response: redirect using non-stigmatizing, family-based, motivational interviewing approach

— 16-year-old previously BMI 32, now 24 after restrictive eating and 20 lb loss in 2 months, bradycardia, amenorrhea.

— Best next step: treat as eating disorder; do not congratulate weight loss; consider admission for medical stabilization

Stem 1 — Initial management:

Stem 2 — Pharmacotherapy candidate:

Stem 3 — Surgery candidate:

Stem 4 — Secondary obesity:

Stem 5 — SCFE:

Stem 6 — MASLD:

Stem 7 — T2DM at diagnosis:

Stem 8 — Monogenic obesity clue:

Stem 9 — Ethics/stigma:

Stem 10 — Atypical AN trap:

Board pearl: When two answers seem reasonable, choose the one that adds to ongoing lifestyle therapy rather than replaces it — IHBLT is foundational at every stage.

One-Line Recap

Pediatric obesity is a chronic, treatable disease defined by BMI ≥95th percentile that demands immediate, intensive, family-based behavioral treatment (≥26 contact hours), with pharmacotherapy (GLP-1 agonists preferred) at age ≥12 and metabolic-bariatric surgery at age ≥13 when severity and comorbidities warrant — guided by the AAP 2023 framework that has abandoned watchful waiting.

Screening: Calculate and plot BMI percentile at every well-child visit ≥2 y (WHO weight-for-length <2 y); USPSTF Grade B for IHBLT ≥6 y; screening labs (lipid, ALT, A1c) at obesity diagnosis ≥10 y or earlier with risk factors

Workup pearls: Short stature with obesity → endocrine/syndromic workup (TSH, Cushing screen, genetics); tall, hyperphagic, early-onset → MC4R/monogenic. Acanthosis nigricans flags insulin resistance — confirm with A1c. ALT cutoffs for MASLD: >44 boys, >22 girls.

Treatment ladder: IHBLT for all → add pharmacotherapy ≥12 y (semaglutide most effective; topiramate teratogenic; GLP-1 contraindicated with MTC/MEN2) → metabolic-bariatric surgery ≥13 y with class 2 obesity + major comorbidity or class 3 (sleeve gastrectomy most common; banding not recommended). Lifelong micronutrient monitoring post-surgery; contraception for 12–18 months post-op.

Don't miss: SCFE (limp + restricted internal rotation → urgent ortho, non–weight-bearing), IIH (papilledema → MRV/LP), atypical anorexia in formerly higher-weight adolescents (same medical risks as classic AN despite "normal" BMI), and weight stigma — use non-stigmatizing, person-first language, motivational interviewing, and family-based approaches at every visit. Address food insecurity before prescribing dietary changes; transition-of-care planning at 18–21 protects against regain and lost follow-up.